Genscript Biotech Corporation (SEHK: 1548)
Health Care · Life Sciences Tools & Services · HK
HK$42.40
-3.02% today · +157.3% 1Y
Genscript Biotech Corporation (SEHK: 1548) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $12.32B and employs 6,135 people.
Over the last twelve months the share price has gained 157.3%, trading between 10.36 and 49.46.
Tweenvest scores Genscript Biotech Corporation across four factors: quality 66/100, value 9/100, growth 100/100. Its strongest factor is growth.
1548 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.32B
- Revenue (TTM)
- $844.97M
- P/E
- —
- EPS
- -0.29
- Dividend yield
- —
- Beta (5Y)
- 0.81
- 52-week high
- HK$49.46
- 52-week low
- HK$10.36
- Avg volume (3M)
- —
- Shares outstanding
- 2.28B
- Employees
- 6,135
- Next earnings
- —
About Genscript Biotech Corporation
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
- ISIN
- KYG3825B1059
- Founded
- 2002
- Listed since
- Dec 30, 2015
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Charles River Laboratories International, Inc.NYSE: CRL | $14.41B | $301.79 | +1.27% |
| WuXi XDC Cayman Inc.SEHK: 2268 | $13.25B | HK$82.10 | +1.86% |
| Tempus AI, Inc.NasdaqGS: TEM | $12.80B | $70.93 | +2.38% |
| ICON Public Limited CompanyNasdaqGS: ICLR | $12.67B | $164.17 | -0.20% |
| Bio-Techne CorporationNasdaqGS: TECH | $11.36B | $72.46 | +0.01% |
| Pharmaron Beijing Co., Ltd.SZSE: 300759 | $10.90B | CN¥43.11 | -4.14% |
| Avantor, Inc.NYSE: AVTR | $10.60B | $15.67 | +1.82% |
| 10x Genomics, Inc.NasdaqGS: TXG | $10.51B | $80.65 | +4.36% |
Figures last refreshed Oct 11, 2026.